US-based, Observational, Drug Registry of Opsumit (Macitentan) New Users in Clinical Practice

Trial Profile

US-based, Observational, Drug Registry of Opsumit (Macitentan) New Users in Clinical Practice

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms OPUS
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2017 Planned End Date changed from 1 Apr 2018 to 30 Apr 2018.
    • 07 Dec 2017 Planned primary completion date changed from 1 Apr 2018 to 30 Apr 2018.
    • 24 May 2017 Results (n=688;data cut off:17 April 2016) assessing patients characteristics,treatment patterns and safety presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top